Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

516

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2025

Conditions

Breast Cancer

Interventions

DRUG

Pertuzumab

Pertuzumab 420 mg i.v. 3-weekly for 3 cycles

DRUG

Trastuzumab

Trastuzumab 6 mg/kg, i.v., 3-weekly for for a total duration of one year

Trial Locations (1)

Helsinki University Hospital, Helsinki

All Listed Sponsors

lead

Helsinki University Central Hospital

OTHER

NCT02625441 - Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer | Biotech Hunter | Biotech Hunter